The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial
Open accessAbstract
Importance: Chronic subdural hematoma (CSDH) is a trauma-associated condition commonly found in elderly patients. Surgery is currently the treatment of choice, but it carries a significant risk of recurrence and death. Nonsurgical treatments remain limited and ineffective. Our recent studies suggest that atorvastatin reduces hematomas and improves the clinical outcomes of patients with CSDH. Objective: To investigate the safety and therapeutic efficacy of atorvastatin to nonsurgically treat patients with CSDH. Design, Setting, and Participants: The Effect of Atorvastatin on Chronic Subdural Hematoma (ATOCH) randomized, placebo-controlled, double-blind phase II clinical trial was conducted in multiple centers in China from February 2014 to November 2015. For this trial, we approached 254 patients with CSDH who received a diagnosis via a computed tomography scan; of these, 200 (78.7%) were enrolled because 23 patients (9.1%) refused to participate and 31 (12.2%) were disqualified. Interventions: Patients were randomly assigned to receive either 20 mg of atorvastatin or placebo daily for 8 weeks and were followed up for an additional 16 weeks. Main Outcomes and Measures: The primary outcome was change in hematoma volume (HV) by computed tomography after 8 weeks of treatment. The secondary outcomes included HV measured at the 4th, 12th, and 24th weeks and neurological function that was evaluated using the Markwalder grading scale/Glasgow Coma Scale and the Barthel Index at the 8th week. Results: One hundred ninety-six patients received treatment (169 men [86.2%]; median [SD] age, 63.6 [14.2] years). The baseline HV and clinical presentations were similar between patients who were taking atorvastatin (98 [50%]) and the placebo (98 [50%]). After 8 weeks, the HV reduction in patients who were taking atorvastatin was 12.55 mL more than those taking the placebo (95% CI, 0.9-23.9 mL; P = .003). Forty-five patients (45.9%) who were taking atorvastatin significantly improved their neurological function, but only 28 (28.6%) who were taking the placebo did, resulting in an adjusted odds ratio of 1.957 for clinical improvements (95% CI, 1.07-3.58; P = .03). Eleven patients (11.2%) who were taking atorvastatin and 23 (23.5%) who were taking the placebo underwent surgery during the trial for an enlarging hematoma and/or a deteriorating clinical condition (hazard ratio, 0.47; 95% CI, 0.24-0.92; P = .03). No significant adverse events were reported. Conclusions and Relevance: Atorvastatin may be a safe and efficacious nonsurgical alternative for treating patients with CSDH. Trial Registration: ClinicalTrials.gov Identifier: NCT02024373.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
The ABCs of Measuring Intracerebral Hemorrhage Volumes
Kothari, R. U., Brott, T., Broderick, J. P., Barsan, W. G., Sauerbeck, L. R., Zuccarello, M., & Khoury, J. (1996) · Stroke · doi:10.1161/01.str.27.8.1304 · Cited by 2,222
Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484
Bakker-Arkema, R. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530260042029 · Cited by 407
Chronic subdural hematoma: a systematic review and meta-analysis of surgical procedures
Liu, W., Bakker, N. A., & Groen, R. J. M. (2014) · Journal of Neurosurgery · doi:10.3171/2014.5.jns132715 · Cited by 334
Gu, Q., Paulose‐Ram, R., Burt, V. L., & Kit, B. K. (2014) · PubMed · Cited by 265
Brennan, P. M., Kolias, A. G., Joannides, A. J., Shapey, J., Marcus, H. J., Gregson, B. A., Grover, P. J., Hutchinson, P. J., & Coulter, I. C. (2017) · Journal of Neurosurgery · doi:10.3171/2016.8.jns16134 · Cited by 237
Wong, G. K. C., Poon, W. S., Chan, M. T. V., Boet, R., Gin, T., Ng, S. C. P., & Zee, B. C. Y. (2010) · Stroke · doi:10.1161/strokeaha.109.571125 · Cited by 215
Self-citationCilla, D. D., Whitfield, L. R., Gibson, D. M., Sedman, A. J., & Posvar, E. L. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90218-0 · Cited by 204
Hohenstein, A., Erber, R., Schilling, L., & Weigel, R. (2005) · Journal of Neurotrauma · doi:10.1089/neu.2005.22.518 · Cited by 142
Cited by
Updates in Chronic Subdural Hematoma: Epidemiology, Etiology, Pathogenesis, Treatment, and Outcome
Feghali, J., Yang, W., & Huang, J. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.06.140 · Cited by 379
Metadata
- Authors
- Jiang, R., Zhao, S., Wang, R., Feng, H., Zhang, J., Li, X., Mao, Y., Yuan, X., Fei, Z., Zhao, Y., Yu, X., Poon, W. S., Zhu, X., Liu, N., Kang, D., Sun, T., Jiao, B., Liu, X., Yu, R., Zhang, J., Gao, G., Hao, J., Su, N., Yin, G., Zhu, X., Lu, Y., Wei, J., Hu, J., Hu, R., Li, J., Wang, D., Wei, H., Tian, Y., Lei, P., Dong, J.-F., & Zhang, J.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-11-01
- Volume
- 75
- Issue
- 11
- Pages
- 1338
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2886480960
- Cited by
- 283
- References
- 23
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. https://app.cochat.ai/papers/10.1001/jamaneurol.2018.2030
- The paper
- Jiang, R., Zhao, S., Wang, R., Feng, H., Zhang, J., Li, X., Mao, Y., Yuan, X., Fei, Z., Zhao, Y., Yu, X., Poon, W. S., Zhu, X., Liu, N., Kang, D., Sun, T., Jiao, B., Liu, X., Yu, R., . . . Zhang, J. (2018). Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2018.2030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.